Investigational Clinical Trials for Hematologic (Blood) Cancers

Hematologic cancers begin in blood-forming tissues such as the bone marrow or in the cells of the immune system. Another name for hematologic cancer is blood cancer. Types of blood cancer include:

Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma (SLL)
Richter’s Transformation (RT)
Mantle Cell Lymphoma (MCL)
Marginal Zone Lymphoma (MZL)
Follicular Lymphoma (FL)

Waldenstrom’s Macroglobulinemia (WM)
Diffuse Large B-Cell Lymphoma (DLBCL)
Burkitt Lymphoma
Multiple Myeloma
Hodgkin Lymphoma
Acute Myeloid Leukemia (AML)

We’re committed to our mission of finding new treatments that may help improve the lives of people with cancer. Our clinical trials for hematologic cancers study investigational medications either alone, in combination with other study medications, or in combination with standard of care therapy. We perform these trials to see if they can help prevent, find, or treat different types of cancer.

Current clinical trials for blood cancers explore investigational medications including: pembrolizumab, vibostolimab, nemtabrutinib, zilovertamab vedotin, or favezelimab.

There is a lot to consider when deciding whether to participate in a clinical trial. Any clinical trial includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.

You can also call our clinical trial information center at 1-888-577-8839 to learn more.